China's New SFDA To Be Dependent, Equal To Other Agencies
This article was originally published in PharmAsia News
China's State FDA is part of a major national government to reorganize the several agencies, with the food and drug one to be elevated to the general administration level, combining oversight responsibilities spread across several other agencies.
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.